Testing Matters INC

Testing Matters INC was paid $1.83M by Medicaid between Jan 2018 and Nov 2023, across 55 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 86% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Florida

Rank by total paid#29 of 225

Median peer was paid$74K

This provider vs. median25×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	5,607	$3K
2019	144	$306.16
2020	4,306	$117K
2021	28,236	$863K
2022	34,316	$791K
2023	3,553	$51K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	86%	29,492	22,092	$1.57M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	4.4%	20,445	15,395	$80K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	3.7%	4,614	3,841	$68K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	2.4%	2,642	2,198	$44K
80074		1.4%	612	536	$26K
80053	Comprehensive metabolic panel	<1%	2,275	1,665	$9K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	539	436	$7K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	1,487	1,269	$3K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	561	354	$3K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	578	509	$3K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	2,374	1,740	$2K
86803		<1%	250	221	$1K

43 more codes

84702		<1%	308	$1K
84443	Thyroid stimulating hormone (TSH)	<1%	599	$1K
83735		<1%	626	$1K
80050	General health panel	<1%	466	$1K
80061	Lipid panel	<1%	777	$1K
80164		<1%	153	$1K
82607		<1%	872	$867.24
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	276	$694.18
86696		<1%	602	$692.35
86769		<1%	26	$659.90
84100		<1%	347	$555.51
86695		<1%	595	$554.34
86592		<1%	757	$516.71
83036	Hemoglobin; glycosylated (A1C)	<1%	748	$418.70
87522	Neg quan hep c or qual rna	<1%	13	$335.84
87521	Neg quan hep c or qual rna	<1%	16	$316.84
80076		<1%	432	$243.84
81003		<1%	736	$204.21
86780		<1%	12	$183.36
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	73	$141.32
82746		<1%	203	$141.00
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	73	$120.26
84436		<1%	72	$95.32
82140		<1%	18	$81.04
87536		<1%	12	$52.88
80048	Basic metabolic panel (calcium, ionized)	<1%	133	$44.36
84479		<1%	20	$43.90
84439		<1%	15	$36.06
87086	Culture, bacterial; quantitative colony count, urine	<1%	206	$27.00
85610		<1%	346	$23.94
83540		<1%	147	$17.63
84550		<1%	84	$16.20
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	30	$14.74
87340		<1%	86	$6.93
84295		<1%	15	$3.24
82043		<1%	69	$2.98
85730		0%	85	$0.00
84153		0%	13	$0.00
83090		0%	33	$0.00
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	0%	72	$0.00
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	0%	66	$0.00
82565		0%	14	$0.00
82570		0%	47	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBOGDAN, MICHAEL (CEO)